Insider transactions

EDGAR

QUOIN PHARMACEUTICALS LTD.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
4 transactions, 57,370 shares
Sum of shares × price per share: 279,965.6
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–19 of 19

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-31 Filed 2026-09-01Lawlor Sally Bridget Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

ADSs
Acquired (A)10,2444.88
49,990.72

Derived: shares × price per share. Exact value 49990.72.

10,684Direct (D) No
F1, F2
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
Open filing 0001104659-26-104403 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Lawlor Sally Bridget Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Ordinary Warrants (Right to Buy) — underlying ADS (5,122) — exercise price 6.10
Acquired (A)5,122——5,122Direct (D) No
F2, F3, F4, F1
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
  • F3 The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
  • F4 The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
Open filing 0001104659-26-104403 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Carter Denise P. Director · Officer: Chief Operating Officer
P

Open market or private purchase of non-derivative or derivative security

ADSs
Acquired (A)20,4904.88
99,991.2

Derived: shares × price per share. Exact value 99991.20.

37,709Direct (D) No
F1, F2
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
Open filing 0001104659-26-104405 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Carter Denise P. Director · Officer: Chief Operating Officer
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Ordinary Warrants (Right to Buy) — underlying ADS (10,245) — exercise price 6.10
Acquired (A)10,245——10,245Direct (D) No
F2, F3, F4, F1
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
  • F3 The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
  • F4 The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
Open filing 0001104659-26-104405 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Myers Michael Director · Officer: Chief Executive Officer
P

Open market or private purchase of non-derivative or derivative security

ADSs
Acquired (A)20,4904.88
99,991.2

Derived: shares × price per share. Exact value 99991.20.

37,713Direct (D) No
F1, F2
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
Open filing 0001104659-26-104404 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Myers Michael Director · Officer: Chief Executive Officer
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Ordinary Warrants (Right to Buy) — underlying ADS (10,245) — exercise price 6.10
Acquired (A)10,245——10,245Direct (D) No
F2, F3, F4, F1
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
  • F3 The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
  • F4 The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
Open filing 0001104659-26-104404 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Culverwell Anthony James Director
P

Open market or private purchase of non-derivative or derivative security

ADSs
Acquired (A)6,1464.88
29,992.48

Derived: shares × price per share. Exact value 29992.48.

40,364Direct (D) No
F1, F2
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
Open filing 0001104659-26-104402 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-01Culverwell Anthony James Director
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Ordinary Warrants (Right to Buy) — underlying ADS (3,073) — exercise price 6.10
Acquired (A)3,073——3,073Direct (D) No
F2, F3, F4, F1
  • F2 Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (Warrants) were issued at a combined purchase price of $4.88.
  • F3 The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
  • F4 The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
Open filing 0001104659-26-104402 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-28Culverwell Anthony James Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

ADSs
Acquired (A)31,3525.15
161,462.8

Derived: shares × price per share. Exact value 161462.80.

34,218Direct (D) No
F1, F2
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
  • F2 On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $161,461 of accrued interest outstanding (Outstanding Debt) owed in connection with a note previously purchased by the Reporting Person was exchanged for 31,352 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.
Open filing 0001104659-26-103374 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-28LANGER DENNIS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

ADSs
Acquired (A)34,5345.15
177,850.1

Derived: shares × price per share. Exact value 177850.10.

56,243Direct (D) No
F1, F2
  • F1 Ordinary Shares are represented by American Depositary Shares (ADSs). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
  • F2 On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $177,849 of accrued interest outstanding (Outstanding Debt) owed in connection with a note previously purchased by the Reporting Person was exchanged for 34,534 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.
Open filing 0001104659-26-103376 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06Lawlor Sally Bridget Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (85,250) — exercise price 7.37
Acquired (A)85,2500—85,250Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011623 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06Culverwell Anthony James Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (21,709) — exercise price 7.37
Acquired (A)21,7090—21,709Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011617 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06Cooper Joseph Patrick Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (8,141) — exercise price 7.37
Acquired (A)8,1410—8,141Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011622 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06SEMBER MICHAEL T Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (8,141) — exercise price 7.37
Acquired (A)8,1410—8,141Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011610 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06Leong Natalie Ee Mun Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (12,211) — exercise price 7.37
Acquired (A)12,2110—12,211Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011608 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06Carter Denise P. Director · Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (318,750) — exercise price 7.37
Acquired (A)318,7500—318,750Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011615 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06Myers Michael Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (318,750) — exercise price 7.37
Acquired (A)318,7500—318,750Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011616 Read from the filing’s XML Dispute this row
2026-02-04 Filed 2026-02-06LANGER DENNIS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (21,709) — exercise price 7.37
Acquired (A)21,7090—21,709Direct (D) No
F1, F2
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Open filing 0001104659-26-011613 Read from the filing’s XML Dispute this row
2025-12-01 Filed 2025-12-03Lawlor Sally Bridget Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Share Option (Right to Buy) — underlying ADS (10,330) — exercise price 19.36
Acquired (A)10,3300—10,330Direct (D) No
F1, F2, F3
  • F1 The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares (ADSs). Each ADS represents thirty-five ordinary shares of the Issuer.
  • F2 The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025.
  • F3 The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029.
Open filing 0001104659-25-118190 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–25 of 25

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Stonepine Capital Management, LLC 252,434 SH1,151,099 dollarsHigher by 52,948 Prior quarter: 199,486Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
SPHERA FUNDS MANAGEMENT LTD. Partly reported under another manager236,234 SH1,077,227 dollarsNot in the prior quarter’s filings read Open filing 0001496201-26-000006 Filed 2026-11-16 Dispute this row
AIGH Capital Management LLC Partly reported under another manager236,234 SH1,077,227 dollarsHigher by 166,234 Prior quarter: 70,000Open filing 0001214659-26-013578 Filed 2026-11-02 Dispute this row
Nantahala Capital Management, LLC 236,234 SH1,077,227 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-127125 Filed 2026-11-13 Dispute this row
STEMPOINT CAPITAL LP 236,234 SH1,077,227 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002774 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 236,227 SH1,048,708 dollarsHigher by 123,904 Prior quarter: 112,323Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC 211,538 SH964,613 dollarsUnchanged Prior quarter: 211,538Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
Empery Asset Management, LP 204,910 SH934,390 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008014 Filed 2026-11-16 Dispute this row
Dauntless Investment Group, LLC 193,937 SH884,353 dollarsLower by 21,050 Prior quarter: 214,987Open filing 0002071844-26-001894 Filed 2026-11-16 Dispute this row
J. Goldman Co LP 190,192 SH867,276 dollarsNot in the prior quarter’s filings read Open filing 0001412741-26-000004 Filed 2026-11-16 Dispute this row
DIADEMA PARTNERS LP 146,446 SH667,794 dollarsNot in the prior quarter’s filings read Open filing 0001892688-26-000170 Filed 2026-11-16 Dispute this row
DAFNA Capital Management LLC 132,156 SH602,631 dollarsNot in the prior quarter’s filings read Open filing 0001389933-26-000010 Filed 2026-11-16 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC 59,838 SH272,861 dollarsUnchanged Prior quarter: 59,838Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
NANO CAP NEW MILLENNIUM GROWTH FUND L P Partly reported under another manager50,000 SH228,000 dollarsNot in the prior quarter’s filings read Open filing 0001277890-26-000005 Filed 2026-11-13 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager20,307 SH92,600 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager19,456 SH88,719 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager8,000 SH36,480 dollarsUnchanged Prior quarter: 8,000Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
RHUMBLINE ADVISERS 3,169 SH14,445 dollarsHigher by 837 Prior quarter: 2,332Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
GAMMA Investing LLC Partly reported under another manager3,116 SH14,209 dollarsHigher by 2,677 Prior quarter: 439Open filing 0002010235-26-000007 Filed 2026-10-08 Dispute this row
Nuveen, LLC Partly reported under another manager437 SH2,133 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Arax Advisory Partners Partly reported under another manager171 SH780 dollarsNot in the prior quarter’s filings read Open filing 0001586767-26-000009 Filed 2026-11-12 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager136 SH620 dollarsNot in the prior quarter’s filings read Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
SBI Securities Co., Ltd. 128 SH584 dollarsLower by 227 Prior quarter: 355Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
Caitong International Asset Management Co., Ltd 9 SH41 dollarsNot in the prior quarter’s filings read Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
NISA INVESTMENT ADVISORS, LLC 4 SH18 dollarsNot in the prior quarter’s filings read Open filing 0000937615-26-000007 Filed 2026-10-20 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • SummitTX Capital, L.P. 100,300 SH
  • Woodline Partners LP 76,446 SH
  • Aberdeen Group plc 75,000 SH
  • Soleus Capital Management, L.P. 72,730 SH
  • Velan Capital Investment Management LP 32,372 SH
  • BARCLAYS PLC 21,469 SH
  • Birchview Capital, LP 20,000 SH
  • XTX Topco Ltd 15,006 SH
  • UBS Group AG 6,772 SH
  • HUNTINGTON NATIONAL BANK 1 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Integrated Core Strategies (US) LLC Ordinary Shares, no par value per share4.998,396,903.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128525 Dispute this row
Millennium Management LLC Ordinary Shares, no par value per share4.998,396,903.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128525 Dispute this row
Millennium Group Management LLC Ordinary Shares, no par value per share4.998,396,903.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128525 Dispute this row
Israel A. Englander Ordinary Shares, no par value per share4.998,396,903.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128525 Dispute this row
StemPoint Capital LP American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share9.9506,983.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001104659-26-127778 Dispute this row
StemPoint Capital Management GP LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share9.9506,983.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001104659-26-127778 Dispute this row
Michelle Ross American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share9.9506,983.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001104659-26-127778 Dispute this row
Ikarian Capital, LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share4.4211,538.0009/30/2026 Filed 2026-10-07SCHEDULE 13G/AAmendment 2Open filing 0001778253-26-000004 Dispute this row
Neil Shahrestani American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share4.4211,538.0009/30/2026 Filed 2026-10-07SCHEDULE 13G/AAmendment 2Open filing 0001778253-26-000004 Dispute this row
Integrated Core Strategies (US) LLC Ordinary Shares, no par value per share5.53,850,385.0005/26/2026 Filed 2026-06-02SCHEDULE 13GOpen filing 0001104659-26-069556 Dispute this row
Millennium Management LLC Ordinary Shares, no par value per share5.53,850,385.0005/26/2026 Filed 2026-06-02SCHEDULE 13GOpen filing 0001104659-26-069556 Dispute this row
Millennium Group Management LLC Ordinary Shares, no par value per share5.53,850,385.0005/26/2026 Filed 2026-06-02SCHEDULE 13GOpen filing 0001104659-26-069556 Dispute this row
Israel A. Englander Ordinary Shares, no par value per share5.53,850,385.0005/26/2026 Filed 2026-06-02SCHEDULE 13GOpen filing 0001104659-26-069556 Dispute this row
Aberdeen Group plc American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share4.1675,00004/01/2026 Filed 2026-04-29SCHEDULE 13G/AAmendment 1Open filing 0001716774-26-000012 Dispute this row
abrdn Inc. American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share4.1675,00004/01/2026 Filed 2026-04-29SCHEDULE 13G/AAmendment 1Open filing 0001716774-26-000012 Dispute this row
ADAR1 Capital Management, LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share4.9102,846.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-062875 Dispute this row
ADAR1 Capital Management GP, LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share4.9102,883.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-062875 Dispute this row
Daniel Schneeberger American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share4.9102,846.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-062875 Dispute this row
Stonepine Capital Management, LLC Ordinary Shares9.997,594,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000935836-26-000279 Dispute this row
Stonepine Capital, L.P. Ordinary Shares9.997,594,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000935836-26-000279 Dispute this row
Stonepine GP, LLC Ordinary Shares9.997,594,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000935836-26-000279 Dispute this row
Jon M. Plexico Ordinary Shares9.997,594,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000935836-26-000279 Dispute this row
Woodline Partners LP Ordinary Shares, no par value per share4.42,785,370.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003240 Dispute this row
Ikarian Capital, LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share12.6211,53801/31/2026 Filed 2026-02-06SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-041438 Dispute this row
Neil Shahrestani American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share12.6211,53801/31/2026 Filed 2026-02-06SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-041438 Dispute this row
Stonepine Capital Management, LLC Ordinary Shares10.63,271,100.0001/29/2026 Filed 2026-02-02SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000065 Dispute this row
Stonepine Capital, L.P. Ordinary Shares10.63,271,100.0001/29/2026 Filed 2026-02-02SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000065 Dispute this row
Stonepine GP, LLC Ordinary Shares10.63,271,100.0001/29/2026 Filed 2026-02-02SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000065 Dispute this row
Jon M. Plexico Ordinary Shares10.63,271,100.0001/29/2026 Filed 2026-02-02SCHEDULE 13G/AAmendment 1Open filing 0000935836-26-000065 Dispute this row
Woodline Partners LP Ordinary Shares, no par value per share9.52,785,370.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0000902664-26-001060 Dispute this row
ADAR1 Capital Management, LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share6.958,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0001104659-26-016659 Dispute this row
ADAR1 Capital Management GP, LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share6.050,226.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0001104659-26-016659 Dispute this row
Daniel Schneeberger American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share6.958,230.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0001104659-26-016659 Dispute this row
Integrated Core Strategies (US) LLC Ordinary Shares, no par value per share4.62,618,595.0012/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-013497 Dispute this row
Millennium Management LLC Ordinary Shares, no par value per share4.62,618,595.0012/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-013497 Dispute this row
Millennium Group Management LLC Ordinary Shares, no par value per share4.62,618,595.0012/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-013497 Dispute this row
Israel A. Englander Ordinary Shares, no par value per share4.62,618,595.0012/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-013497 Dispute this row
Aberdeen Group plc American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share8.9475,00012/31/2025 Filed 2026-01-28SCHEDULE 13GOpen filing 0001716774-26-000006 Dispute this row
abrdn Inc. American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share8.9475,00012/31/2025 Filed 2026-01-28SCHEDULE 13GOpen filing 0001716774-26-000006 Dispute this row
Stonepine Capital Management, LLC Ordinary Shares9.93,030,926.0012/10/2025 Filed 2025-12-16SCHEDULE 13GOpen filing 0000935836-25-000719 Dispute this row
Stonepine Capital, L.P. Ordinary Shares9.93,030,926.0012/10/2025 Filed 2025-12-16SCHEDULE 13GOpen filing 0000935836-25-000719 Dispute this row
Stonepine GP, LLC Ordinary Shares9.93,030,926.0012/10/2025 Filed 2025-12-16SCHEDULE 13GOpen filing 0000935836-25-000719 Dispute this row
Jon M. Plexico Ordinary Shares9.93,030,926.0012/10/2025 Filed 2025-12-16SCHEDULE 13GOpen filing 0000935836-25-000719 Dispute this row
Ikarian Capital, LLC American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share25.2211,53811/30/2025 Filed 2025-12-15SCHEDULE 13GOpen filing 0001193125-25-319730 Dispute this row
Neil Shahrestani American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share25.2211,53811/30/2025 Filed 2025-12-15SCHEDULE 13GOpen filing 0001193125-25-319730 Dispute this row
Integrated Core Strategies (US) LLC Ordinary Shares, no par value per share9.01,901,585.0010/20/2025 Filed 2025-10-27SCHEDULE 13GOpen filing 0001104659-25-102609 Dispute this row
Millennium Management LLC Ordinary Shares, no par value per share9.01,901,585.0010/20/2025 Filed 2025-10-27SCHEDULE 13GOpen filing 0001104659-25-102609 Dispute this row
Millennium Group Management LLC Ordinary Shares, no par value per share9.01,901,585.0010/20/2025 Filed 2025-10-27SCHEDULE 13GOpen filing 0001104659-25-102609 Dispute this row
Israel A. Englander Ordinary Shares, no par value per share9.01,901,585.0010/20/2025 Filed 2025-10-27SCHEDULE 13GOpen filing 0001104659-25-102609 Dispute this row
Resolute Capital Asset Partners LLC American Depositary Shares, Each representing thirty-five(35) ordinary shares, no par value per share8.550,000.0010/10/2025 Filed 2025-12-11SCHEDULE 13GOpen filing 0001834913-25-000006 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,715,586 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015131,968
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to QUOIN PHARMACEUTICALS LTD.